Quantcast

Latest Low dose naltrexone Stories

2011-09-02 12:19:40

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically (off-label) to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation. It has been postulated that opioid receptor blockade by LDN provokes a compensatory elevation in endogenous opioids and opioid receptors that can function after LDN is no...

2011-07-12 22:35:33

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis. This discovery, reported in the July 2011 issue of Experimental Biology and Medicine, provides new...

2009-08-25 10:49:00

CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. The Phase Ib multiple-ascending dose, double-blind, placebo-controlled, randomized...

2009-04-29 12:47:00

Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange. MILWAUKEE, April 29 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center in Milwaukee report that plasma exchange therapy or PLEX dramatically improves the health of multiple sclerosis patients who fail to respond to conventional therapies. (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b) "There is no other treatment that brings about such a reversal in multiple sclerosis," says...

2009-04-23 13:45:47

An inexpensive drug that has been used for years to treat opioid addiction may be the key to relieving pain for millions of fibromyalgia sufferers. Fibromyalgia is a disorder that affects an estimated 4 percent of the population, yet there is no well-established and objective blood test to confirm its diagnosis. Sufferers report experiencing chronic widespread pain, debilitating fatigue, sleep disturbance and joint disorders. A small pilot study at Stanford University tested the effect of a...

2009-03-03 10:36:40

Multiple sclerosis patients may benefit from the drug fampridine. In a new study conducted in centers in the U.S. and Canada, those who received the drug were able to walk faster on standard tests than those who received a placebo for comparison purposes. Leg strength improved more significantly in people taking the active drug as well. The findings held true across a range of MS disease course types. "Treatment with fampridine produces clinically meaningful improvement in walking ability in...

2008-10-07 12:00:19

By JULIA HORTON SCOTTISH scientists claim to have developed a "breakthrough" test that could lead to new medication for thousands of multiple sclerosis patients whose condition is currently untreatable. Researchers at life sciences company Glasgow Health Solutions (GHS) revealed yesterday they have devised a blood test that detects levels of nitrotyrosine, a "bio marker" whose presence indicates chemical activity hat causes the nerve-cell damage that results in MS. Early detection...

2008-10-06 09:00:57

PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today presented data showing the investigational drug, Contrave(R) (naltrexone SR / bupropion SR), successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials. In addition, preliminary analysis of blinded data from nearly 4,000 patients...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related